繁體
简体中文
繁體中文

Mairs & Power明尼蘇達州市政債券主動型ETF MINN 深 滬

已收盤 11-20 16:00:00 美东时间

21.47

+0.070

+0.33%

华盛通華盛通
立即下載
  • 最 高21.53
  • 今 開21.475
  • 成交量 1.47万股
  • 最 低 21.45
  • 昨 收 21.40
  • 總市值 5388.97万
  • 52周最高 22.7404
  • 市盈率 靜 --
  • 換手率 0.58%
  • 52周最低 20.4431
  • 委 比 -79.38%
  • 總股本 251.00万
  • 歷史最高 22.9025
  • 量 比 1.10
  • 振 幅 0.37%
  • 歷史最低 18.1192
  • 每 手 1
  • 風險率 0.39%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Inspire Medical Systems, Inc. to Present at the Piper Sandler 38th Annual Healthcare Conference

    Inspire Medical Systems announced that its management team will present at the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026, at 3:00 p.m. Eastern Time. The presentation will be available via live webcast and replay for two weeks on Inspire’s Investor website. Inspire, a medical technology company, specializes in innovative, minimally invasive solutions for obstructive sleep apnea, with its FDA, EU MDR, and PDMA-approved Ins...

    11-17 21:05

  • OneMedNet Reports Third Quarter 2026 Financial Results and Reiterates Fourth Quarter 2026 Outlook

    OneMedNet reported Q3 2026 revenue of $1.02 million, up 250% Q/Q and 478% Y/Y. The company reaffirms Q4 2026 revenue guidance of $12-$14 million, driven by growing demand and scaled data delivery. CEO Aaron Green highlighted strong momentum and progress in delivering regulatory-grade real-world data.

    11-17 14:15

  • Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

    Celcuity Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for REVTORPYK™ (gedatolisib) to treat HR+/HER2- locally advanced or metastatic breast cancer (ABC) with a <em>PIK3CA</em> mutation. The FDA assigned a PDUFA goal date of June 25, 2027. The submission is based on clinical data from the <em>PIK3CA</em> mutant cohort of the Phase 3 VIKTORIA-1 trial. If approved, REVTORPYK would become available as a second...

    11-09 13:30

  • Nuwellis to Report Third Quarter 2026 Financial Results on November 12

    Nuwellis, Inc. (Nasdaq: NUWE) will report financial results for the third and first nine months of 2026 before U.S. markets open on November 12, 2026. A conference call will follow at 9:00 a.m. Eastern time. The call can be accessed via phone or webcast, with details provided. Nuwellis focuses on medical technology solutions for cardiorenal conditions.

    11-04 13:30

  • Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference

    <p>MINNEAPOLIS, Nov. 03, 2026 -- Inspire Medical Systems, Inc. announced that its management team will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 2:40 p.m. Eastern Time. The presentation will be available via live webcast and a replay will be accessible for two weeks post-event on Inspire’s Investor website. Inspire, a medical technology company, focuses on developing innovative solutions for obstructive sleep apnea...

    11-03 21:05

  • OneMedNet Receives High Six-Figure Add-On Order Under Multiyear Agreement Announced September 30

    OneMedNet Corporation announced a high six-figure add-on order under its September 2026 agreement, increasing data volume by 150% to support a customer's derivative data offering. The customer, leveraging OneMedNet's de-identified, multimodal clinical data, aims to train AI models and develop a licensable dataset. The order reflects the customer's need for additional data within weeks of the initial agreement. OneMedNet's data, sourced from over ...

    11-03 13:40

  • CVRx to Participate in Upcoming Investor Conferences

    CVRx, Inc. announced that its management team will participate in two investor conferences: the Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum in New York on Nov. 11, 2026, and the Jefferies Global Healthcare Conference in London on Nov. 19, 2026. Both events will be available via webcast. CVRx, a medical device company, focuses on developing neuromodulation solutions for cardiovascular diseases, including Barostim, an FDA...

    11-02 21:01

  • Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

    Nuwellis, Inc. announced the publication of a study in *Pediatric Nephrology* highlighting the effectiveness of its Aquadex SmartFlow® System in pediatric patients, including infants weighing less than 10 kg. The ULTRA-Peds Registry evaluated 91 pediatric patients across seven hospitals, demonstrating 87% survival and 86.5% uninterrupted procedures. The study provides clinical evidence to support expanding Aquadex's FDA-cleared labeling for patie...

    10-27 12:00

  • Park Dental Partners Announces Dates for Third Quarter 2026 Earnings Release and Conference Call

    Park Dental Partners, Inc. announced it will release its Q3 2026 financial results after market close on November 12, 2026. A conference call to discuss the results will be held the next day at 8:30 a.m. ET (7:30 a.m. CT). The call can be accessed via webcast or phone, with replay available on the company's website. Park Dental Partners, based in Roseville, MN, provides comprehensive support services to its affiliated dental practices, with 222 d...

    10-26 20:13

  • Clearfield Announces CEO Succession Plan

    Clearfield, Inc. announced that CEO Cheri Beranek will retire effective March 31, 2027, and will transition to an emeritus role. The Board of Directors will begin the search for her successor, considering both internal and external candidates. Beranek has led Clearfield for two decades, driving growth and innovation. The company remains on track for its financial targets and expects to report Q4 and full-year 2026 results on November 10, 2026.

    10-20 11:00